CKD Bio Corp. (KRX:063160)

South Korea flag South Korea · Delayed Price · Currency is KRW
21,600
+100 (0.47%)
Last updated: Jan 28, 2026, 10:58 AM KST
-3.36%
Market Cap117.67B -2.3%
Revenue (ttm)159.93B +3.6%
Net Income-23.13B
EPS-4,216.38
Shares Out5.49M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume31,190
Average Volume133,509
Open21,500
Previous Close21,500
Day's Range21,300 - 21,900
52-Week Range19,060 - 27,650
Beta0.69
RSI55.50
Earnings DateAug 14, 2025

About CKD Bio

CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea. [Read more]

Sector Healthcare
Founded 1941
Employees 519
Stock Exchange Korea Stock Exchange
Ticker Symbol 063160
Full Company Profile

Financial Performance

In 2022, CKD Bio's revenue was 156.04 billion, an increase of 9.70% compared to the previous year's 142.24 billion. Losses were -16.70 billion, 154.0% more than in 2021.

Financial Statements